Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics最新文献

Clinical correlations of adriamycin pharmacology 阿霉素药理学的临床相关性

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1978-01-01 DOI: 10.1016/S0362-5486(78)80001-6

Steven D. Reich

{"title":"Clinical correlations of adriamycin pharmacology","authors":"Steven D. Reich","doi":"10.1016/S0362-5486(78)80001-6","DOIUrl":"10.1016/S0362-5486(78)80001-6","url":null,"abstract":"<div><p>Adriamycin is an effective antineoplastic agent with dose-limiting acute toxicity and a cumulative dose-dependent cardiotoxicity. It undergoes extensive biotransformation to both active and inactive compounds; changes in metabolism may affect its therapeutic index.</p><p>Hepatic metabolism and bile secretion are the major routes of drug elimination. Factors which affect liver function, whether disease-related or due to concomitant drug administration, may affect both adriamycin efficacy and toxicity.</p><p>Cardiomyopathy due to adriamycin has a biochemical basis, but presently the mechanisms are unknown. Methods to avoid this complication are under study.</p><p>Consideration of the cytokinetics of normal and tumor cells may be as important in planning adriamycin combinations as is consideration of drug-drug interactions.</p><p>Because of its broad spectrum of action and high antitumor activity, adriamycin is used in many cancer patients both as a single agent and in combination with other drugs. An understanding of the pharmacology of this drug by the physicians who administer it will lead to better selection of appropriate patients, drug combinations and dosage schedules. This increased awareness of adriamycin pharmacology should be translated into safer, more efficacious therapy for cancer patients.</p></div>","PeriodicalId":101017,"journal":{"name":"Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics","volume":"2 3","pages":"Pages 239-249"},"PeriodicalIF":0.0,"publicationDate":"1978-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0362-5486(78)80001-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82727120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

The teratogenicity of antiepileptic drugs 抗癫痫药物的致畸性

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1978-01-01 DOI: 10.1016/S0362-5486(78)80003-X

Susan Boobis

引用次数: 8

Clinical consequences of microsomal enzyme-induction by antiepileptic drugs 抗癫痫药物诱导微粒体酶的临床效果

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1978-01-01 DOI: 10.1016/S0362-5486(78)80004-1

Emilio Perucca

引用次数: 36

Clinical pharmacokinetics of antiepileptic drugs in children 儿童抗癫痫药物的临床药代动力学

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1978-01-01 DOI: 10.1016/S0362-5486(78)80002-8

Anders Rane

引用次数: 10

The use of androgens in the treatment of neoplastic disease 雄激素在肿瘤疾病治疗中的应用

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1977-01-01 DOI: 10.1016/S0362-5486(77)80010-1

Albert Segaloff

引用次数: 24

Clinical studies of gonadotropins in the male 男性促性腺激素的临床研究

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1977-01-01 DOI: 10.1016/S0362-5486(77)80008-3

Eugenia Rosemberg (Research Director, Research Professor)

引用次数: 1

Androgens in nephrology 肾脏学中的雄激素

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1977-01-01 DOI: 10.1016/S0362-5486(77)80012-5

Joseph B. Rosenfeld (Chief, Associate Professor of Internal Medicine)

引用次数: 0

Thyroid cancer classification, clinical features, diagnosis and therapy 甲状腺癌的分类、临床特征、诊断与治疗

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1977-01-01 DOI: 10.1016/S0362-5486(77)80007-1

Andre J. Van Herle, Robert P. Uller

{"title":"Thyroid cancer classification, clinical features, diagnosis and therapy","authors":"Andre J. Van Herle, Robert P. Uller","doi":"10.1016/S0362-5486(77)80007-1","DOIUrl":"10.1016/S0362-5486(77)80007-1","url":null,"abstract":"<div><p>The topic of thyroid cancer has been highly controversial in all its aspects, but most of all in its histologic classification and its management. The present section is an attempt to crystallize the vast literature in this area. The histology and the ultrastructure of thyroid tumors is discussed. The etiologic factors involved in the development of thyroid cancer are largely unknown; the high incidence of thyroid cancer in Hawaii points to important environmental factors causing malignancies in the thyroid. The importance of radiation to the neck area in childhood is another recognized etiologic factor in the development of thyroid tumors. Isotope scanning techniques are discussed. Ultrasonography is useful for the diagnosis of cystic lesions of the thyroid. Finally the variable surgical procedures used by various authors in the management of differentiated thyroid cancer is reviewed; the rationale for performing a total thyroidectomy in these cases, as advocated by the authors, is discussed. The use of radioiodine therapy following surgery', treatment with suppressive doses of thyroid hormone and the use of adriamycin as a treatment for thyroid cancer uncontrollable by other means are discussed.</p></div>","PeriodicalId":101017,"journal":{"name":"Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics","volume":"2 2","pages":"Pages 215-238"},"PeriodicalIF":0.0,"publicationDate":"1977-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0362-5486(77)80007-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82997834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The use of androgens in the treatment of diseases of the hematopoietic system 雄激素在治疗造血系统疾病中的应用

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1977-01-01 DOI: 10.1016/S0362-5486(77)80011-3

B.J. Kennedy (Professor of Medicine)

{"title":"The use of androgens in the treatment of diseases of the hematopoietic system","authors":"B.J. Kennedy (Professor of Medicine)","doi":"10.1016/S0362-5486(77)80011-3","DOIUrl":"10.1016/S0362-5486(77)80011-3","url":null,"abstract":"<div><p>Stimulation of erythropoiesis has been induced in patients by the administration of massive doses of androgenic hormones. There is an increase in hemoglobin and hematocrit, reticulocytosis, increase in red blood cell mass, development of a normoblastic hyperplasia of the bone marrow, and polycythemia may occur. The extensive studies of the influence of the endocrine glands on the formed elements of the blood in animals and man demonstrate the relationship of erythropoiesis and the androgenic hormone.</p><p>Because of the effect of androgenic hormones on hematopoiesis, these hormones have been employed in the treatment of a variety of hematopoietic diseases. Improvements have been noted in myelofibrosis, chronic lymphatic leukemia, aplastic anemia, and specific refractory anemias. The androgens have been employed as adjuvant therapy to stimulate bone marrow during the chemotherapy of a variety of neoplastic diseases. The androgenic hormones provide a specific treatment as well as an adjuvant therapy in the management of hematological abnormalities.</p></div>","PeriodicalId":101017,"journal":{"name":"Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics","volume":"2 1","pages":"Pages 39-56"},"PeriodicalIF":0.0,"publicationDate":"1977-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0362-5486(77)80011-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88568883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Obesity and thyroid hormone 肥胖与甲状腺激素

Pharmacology & Therapeutics. Part C: Clinical Pharmacology and Therapeutics Pub Date : 1977-01-01 DOI: 10.1016/S0362-5486(77)80006-X

George A. Bray

引用次数: 1